Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial

Table 2 Anthropometric indices at the beginning and after 12 weeks of intervention in women with polycystic ovary syndrome

Characteristics	Intervention group N = 28	Placebo group N = 24	P**
Weight (kg)
Baseline End of trial Change P*	67.17 ± 11.84 66.92 ± 12.55 -0.25 ± 3.24 0.683	66.10 ± 11.45 65.18 ± 10.42 -0.06 ± 2.42 0.903	0.742 0.603 0.820
BMI (kg/m²)
Baseline End of trial Change P*	25.19 ± 4.09 24.09 ± 4.22 -0.10 ± 1.26 0.676	24.86 ± 4.33 24.48 ± 3.73 -0.05 ± 0.90 0.779	0.780 0.592 0.882
WC (cm)
Baseline End of trial Change P*	83.25 ± 10.92 81.96 ± 11.23 -0.79 ± 5.63 0.492	82.66 ± 10.24 82.17 ± 10.62 0.00 ± 5.86 1.000	0.843 0.946 0.642
HC (cm)
Baseline End of trial Change P*	103.46 ± 9.08 102.74 ± 10.74 -0.51 ± 6.02 0.664	102.75 ± 8.68 101.30 ± 8.17 -1.04 ± 3.48 0.165	0.776 0.602 0.716

P*: p-values for comparison within groups via paired t-test.
P**: p-values for comparison between groups via independent t-test.
Abbreviations: CI: confidence interval; BMI: body mass index; WC: waist circumference; HC: hip circumference.

ISSN: 1472-6874